TY - JOUR
T1 - Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies
T2 - Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics
AU - Yu, B.
AU - Carrasquillo, J.
AU - Milenic, D.
AU - Chung, Y.
AU - Perentesis, P.
AU - Feuerestein, I.
AU - Eggensperger, D.
AU - Qi, C. F.
AU - Paik, C.
AU - Reynolds, J.
AU - Grem, J.
AU - Curt, G.
AU - Siler, K.
AU - Schlom, J.
AU - Allegra, C.
PY - 1996/6
Y1 - 1996/6
N2 - Purpose: COL-1 is a high-affinity murine monoclonal antibody (MAb) specific for carcinoembryonic antigen (CEA). A phase I trial was conducted in which a uniform quantity of antibody labeled with escalating doses of iodine 131 (131I) was administered to patients with advanced gastrointestinal (GI) malignancies to evaluate tolerance and pharmacokinetics. Patients and Methods: Eighteen patients with advanced, assessable GI malignancies (16 colon, one pancreas, and one gastric) previously treated with conventional chemotherapy (but no pelvic radiation) received 20 mg of COL-1 labeled with 131I, with doses from 10 mCi/m2 to 75 mCi/m2. In this cohort, the baseline serum CEA level ranged from 6 to 2,739 ng/mL (mean ± SD, 500 ± 639). Results: Nuclear imaging detected at least one tumor site in all 18 patients; 82% of all tumor involved organs were positive and 58% of all lesions ≥ 1.0 cm were detected. Immune complexes were detected in 89% of patients 5 minutes after completion of infusion, and levels correlated with CEA levels (r = .71). Elevated CEA (> 500 ng/mL) and tumor bulk (total tumor area > 150 cm2) correlated directly with clearance of serum radioactivity and inversely with serum half-life and cumulative serum radioactivity parameters. Nonhematologic toxicity was mild and non-dose-limiting. Hematologic toxicity, particularly thrombocytopenia, was both dose-related and dose-limiting. The maximal-tolerated dose is 65 mCi/m2. The correlation between dose (millicuries per square meter) and thrombocytopenia was made stranger, by accounting for either variation in pharmacokinetics, or variation in serum CEA and tumor bulk. Conclusion: 131I-COL-1 is well tolerated, except for hematologic toxicity. These data suggest that patients with highly elevated circulating CEA levels and/or increased tumor bulk may clear 131I-labeled COL-1 more rapidly from the circulation and experience less myelosuppression.
AB - Purpose: COL-1 is a high-affinity murine monoclonal antibody (MAb) specific for carcinoembryonic antigen (CEA). A phase I trial was conducted in which a uniform quantity of antibody labeled with escalating doses of iodine 131 (131I) was administered to patients with advanced gastrointestinal (GI) malignancies to evaluate tolerance and pharmacokinetics. Patients and Methods: Eighteen patients with advanced, assessable GI malignancies (16 colon, one pancreas, and one gastric) previously treated with conventional chemotherapy (but no pelvic radiation) received 20 mg of COL-1 labeled with 131I, with doses from 10 mCi/m2 to 75 mCi/m2. In this cohort, the baseline serum CEA level ranged from 6 to 2,739 ng/mL (mean ± SD, 500 ± 639). Results: Nuclear imaging detected at least one tumor site in all 18 patients; 82% of all tumor involved organs were positive and 58% of all lesions ≥ 1.0 cm were detected. Immune complexes were detected in 89% of patients 5 minutes after completion of infusion, and levels correlated with CEA levels (r = .71). Elevated CEA (> 500 ng/mL) and tumor bulk (total tumor area > 150 cm2) correlated directly with clearance of serum radioactivity and inversely with serum half-life and cumulative serum radioactivity parameters. Nonhematologic toxicity was mild and non-dose-limiting. Hematologic toxicity, particularly thrombocytopenia, was both dose-related and dose-limiting. The maximal-tolerated dose is 65 mCi/m2. The correlation between dose (millicuries per square meter) and thrombocytopenia was made stranger, by accounting for either variation in pharmacokinetics, or variation in serum CEA and tumor bulk. Conclusion: 131I-COL-1 is well tolerated, except for hematologic toxicity. These data suggest that patients with highly elevated circulating CEA levels and/or increased tumor bulk may clear 131I-labeled COL-1 more rapidly from the circulation and experience less myelosuppression.
UR - http://www.scopus.com/inward/record.url?scp=8944222567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8944222567&partnerID=8YFLogxK
U2 - 10.1200/JCO.1996.14.6.1798
DO - 10.1200/JCO.1996.14.6.1798
M3 - Article
C2 - 8656248
AN - SCOPUS:8944222567
SN - 0732-183X
VL - 14
SP - 1798
EP - 1809
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -